Communiqués Orion Oyj

Actions

ORNBV

FI0009014377

Produits pharmaceutiques

PEA

Temps réel estimé Tradegate Autres places de cotation 17:13:45 08/07/2026			Varia. 5j.	Varia. 1 janv.
70,42 ^EUR	-2,05 %		-0,64 %	+10,53 %

06/07	Shilpa Biologicals Private Limited et Orion Corporation renforcent leur partenariat pour le développement et la fourniture d'un biosimilaire du Nivolumab en Europe	CI
30/06	Tenax Therapeutics, Inc. et Orion Corporation concluent un accord d'approvisionnement pour la fabrication et la fourniture de lévosimendan par voie orale	CI

Communiqués

06/07	Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026	AQ
03/07	Orion Oyj : publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026	PU
03/07	Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026	GL
30/06	Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market	GL
23/06	Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission	GL
18/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
17/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
16/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
15/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
11/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
10/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
05/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
01/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
30/05	Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours	GL
21/05	Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting	GL
15/05	105,950 Orion Corporation A shares converted into B shares	GL
15/05	105,950 Orion Corporation A shares converted into B shares	AQ
12/05	Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs	GL
04/05	Orion Corporation: Managers’ transactions – Sophie Papa	GL
04/05	Orion Corporation: Managers’ transactions – Ari Lehtoranta	GL
04/05	Orion Corporation: Managers’ transactions – Ari Lehtoranta	AQ
04/05	Orion Corporation: Managers’ transactions – Sophie Papa	AQ
04/05	Orion Corporation: Managers’ transactions – Karen Lykke Sørensen	GL
04/05	Orion Corporation: Managers’ transactions – Minna Maasilta	GL
04/05	Orion Corporation: Managers’ transactions – Kari Jussi Aho	GL